Epi One is revolutionizing cancer diagnosis through its innovative technology that focuses on early detection, which is crucial for effective treatment and improved survival rates. The company has developed a simple blood test that utilizes advanced DNA-based biomarker identification techniques. This method allows for the accurate diagnosis of cancer within a remarkably short turnaround time of just six hours, significantly faster than traditional screening methods such as X-rays and genomic sequencing, which can take days or even weeks. By streamlining the diagnostic process, Epi One aims to make cancer screening more accessible and affordable, ultimately saving millions of lives each year.

The core of Epi One's technology lies in its highly accurate PCR (Polymerase Chain Reaction) test, which can analyze multiple biomarkers in a single blood draw. This approach not only enhances the precision of cancer detection but also reduces the overall cost to approximately $500 per patient. By providing timely and reliable results, Epi One's solution addresses the critical issue of late cancer diagnoses, which is a leading cause of mortality worldwide. The company's commitment to transforming cancer screening through innovative science positions it as a key player in the fight against cancer.

United States

We are on a mission to build a revolutionary cancer diagnosis platform to solve the challenge of early cancer prognosis and detection, as well as prediction of post-diagnosis cancer drug response.

Epi One

Company Details